There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trillium Therapeutics (TRIL) and Crinetics Pharmaceuticals (CRNX) with bullish sentiments.
Trillium Therapeutics (TRIL)
Bloom Burton analyst David Martin PhD maintained a Buy rating on Trillium Therapeutics on April 29 and set a price target of $20.00. The company’s shares closed last Friday at $9.51.
According to TipRanks.com, PhD is a 5-star analyst with an average return of 30.1% and a 47.1% success rate. PhD covers the Healthcare sector, focusing on stocks such as Chinook Therapeutics, Knight Therapeutics, and Greenbrook Tms.
Currently, the analyst consensus on Trillium Therapeutics is a Strong Buy with an average price target of $23.20, a 160.1% upside from current levels. In a report issued on April 14, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $21.00 price target.
See today’s analyst top recommended stocks >>
Crinetics Pharmaceuticals (CRNX)
In a report released today, Lina Kaminski from JonesTrading initiated coverage with a Buy rating on Crinetics Pharmaceuticals and a price target of $42.00. The company’s shares closed last Friday at $17.31.
According to TipRanks.com, Kaminski is a 1-star analyst with an average return of 0.8% and a 63.6% success rate. Kaminski covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Dyne Therapeutics, and Krystal Biotech.
Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRNX: